Focal Segmental Glomerulosclerosis Clinical Trials

20 recruiting

Focal Segmental Glomerulosclerosis Trials at a Glance

20 actively recruiting trials for focal segmental glomerulosclerosis are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in New York, Philadelphia, and Chapel Hill. Lead sponsors running focal segmental glomerulosclerosis studies include Kaneka Medical America LLC, Northwell Health, and Travere Therapeutics, Inc..

Browse focal segmental glomerulosclerosis trials by phase

Treatments under study

About Focal Segmental Glomerulosclerosis Clinical Trials

Looking for clinical trials for Focal Segmental Glomerulosclerosis? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Focal Segmental Glomerulosclerosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Focal Segmental Glomerulosclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Phase 3

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled256 locationsNCT07220083
Recruiting

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Focal Segmental GlomerulosclerosisMinimal Change DiseaseFSGS+1 more
University of Michigan300 enrolled1 locationNCT05650619
Recruiting
Phase 2

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Akebia Therapeutics60 enrolled10 locationsNCT07268638
Recruiting
Not Applicable

taVNS for FRNS in Children

Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease
Northwell Health30 enrolled2 locationsNCT05588063
Recruiting
Not Applicable

A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)

Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease
Northwell Health10 enrolled2 locationsNCT05583942
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Phase 2

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
Phase 4

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Kidney TransplantFocal Segmental GlomerulosclerosisProteinuria+1 more
Travere Therapeutics, Inc.20 enrolled9 locationsNCT07219121
Recruiting
Not Applicable

NEPTUNE Match Study

Nephrotic Syndrome in ChildrenAlport SyndromeFocal Segmental Glomerulosclerosis+6 more
University of Michigan375 enrolled16 locationsNCT04571658
Recruiting
Phase 1Phase 2

AMPK-activation by Metformin in FSGS: AMP-FSGS

Focal Segmental Glomerulosclerosis
Yale University30 enrolled2 locationsNCT06090227
Recruiting
Phase 2

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting
Phase 1

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Otsuka Pharmaceutical Development & Commercialization, Inc.30 enrolled6 locationsNCT06799520
Recruiting
Not Applicable

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC35 enrolled12 locationsNCT02235857
Recruiting
Phase 1

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

Focal Segmental GlomerulosclerosisIgA Nephropathy
Hansoh BioMedical R&D Company84 enrolled1 locationNCT05942625
Recruiting
Not Applicable

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC35 enrolled10 locationsNCT04065438
Recruiting

ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank

Focal Segmental GlomerulosclerosisProteinuriaNephrotic Syndrome+1 more
Christoph Aufricht100 enrolled1 locationNCT06162546
Recruiting

National Registry of Rare Kidney Diseases

Denys-Drash SyndromeTuberous SclerosisAutosomal Recessive Polycystic Kidney Disease+81 more
UK Kidney Association35,000 enrolled1 locationNCT06065852
Recruiting
Phase 3

A Pivotal Phase 3 Study of the Efficacy and Safety of DMX-200 in Patients With focal segmental glomerulosclerosis (FSGS) Who Are Receiving an angiotensin II receptor blocker (ARB)

Focal segmental glomerulosclerosis (FSGS)
Dimerix Bioscience Pty Ltd286 enrolled20 locationsACTRN12622000066785
Recruiting

KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Focal Segmental GlomerulosclerosisIgA NephropathyMembranous Nephropathy+4 more
Seoul National University Hospital3,000 enrolled6 locationsNCT03929887